| Document |
Document Title |
|
WO/2024/078283A1 |
The present invention belongs to the field of medicine, and specifically relates to crisaborole or a pharmaceutically acceptable salt aqueous solution composition thereof, comprising an amino acid or a derivative thereof. The crisaborole...
|
|
WO/2024/078468A1 |
The present invention relates to use of a stilbene derivative in the prevention and/or treatment of ulcers. A compound of formula (I) or a pharmaceutically acceptable salt thereof can effectively prevent or treat ulcers, and in particula...
|
|
WO/2024/080400A1 |
The present invention relates to a peptide having activity in promoting hair growth or preventing or suppressing alopecia. The peptide according to the present invention promotes the proliferation of hair follicle dermal papilla cells (H...
|
|
WO/2024/076921A1 |
An acne treatment composition that contains a mixture of rhamnolipid salts is disclosed. The composition has efficacy against C. acnes. Also disclosed is a method for controlling, treating, or preventing acne in a subject.
|
|
WO/2024/074116A1 |
The present invention relates to use of a compound represented by formula (I) or an ester thereof or a pharmaceutically acceptable salt thereof in the treatment of a disease accompanied by fibrosis.
|
|
WO/2024/075686A1 |
Provided is a skin resident flora improving agent useful for keeping the skin in a good condition. In the skin resident flora improving agent, sophorose is used. Sophorose is provided with a function of making it possible to encourage pr...
|
|
WO/2024/075044A1 |
The present invention relates to a liquid crystal emulsion comprising: i) a fatty phase containing: at least one mono- and diglyceride of C12-C22 fatty acids; at least one butter; at least one oil; at least one alkylpolyglucoside, in whi...
|
|
WO/2024/075968A1 |
The present invention relates to a composition for external application to the skin, having an excellent skin improvement effect.
|
|
WO/2024/074700A1 |
The present invention relates to topical compositions comprising an estetrol component and the use of said compositions to deliver an effective amount of an estetrol component to the skin, particularly for wound healing. Optionally, the ...
|
|
WO/2024/075844A1 |
The present disclosure provides a technique for examining the acquisition risk of an inflammatory skin disease, the severity or the degree of progression thereof. The present disclosure provides a method for analyzing a biological sample...
|
|
WO/2024/075809A1 |
The purpose of the present invention is to provide an antimicrobial agent having reduced allergy properties and containing recombinant psLAAO, and a method for producing this antimicrobial agent. This purpose is solved by an antimicrobia...
|
|
WO/2024/075937A1 |
The present invention relates to a composition comprising a fucoidan fermentation product, and use thereof for improving the condition of the skin. Since low-molecular weight fucoidan can be induced when fucoidan is fermented using a Lac...
|
|
WO/2024/076173A1 |
Disclosed are a composition for inducing differentiation of adipose-derived stem cells into dermal papilla cells, and a differentiation method using the composition. The composition for inducing differentiation and the differentiation me...
|
|
WO/2024/077310A1 |
A preparation comprising the YEL002 compound as an active ingredient for the prevention or treatment of one or more diseases or conditions, and methods of using such preparations. The preparations may be a sublingual pill, an injection, ...
|
|
WO/2024/077018A2 |
Provided herein are methods of treatment and uses involving an immunomodulatory TACI-Fc fusion protein that exhibits neutralizing activity of BAFF and APRIL (or BAFF/ APRIL heterotrimers). The provided TACI-Fc protein may include variant...
|
|
WO/2024/067531A1 |
Provided is a dual-targeting compound against FAP and integrin αvβ3. The targeting compound and a radionuclide marker thereof can synergistically target a FAP target and an integrin αvβ3 target in tumors, such that the number of and ...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/068851A1 |
A novel process for preparation of crystalline forms and novel crystalline forms of 1-(8- bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-meth
ylazetidin-3-amine salts is provided along with pharmaceutical compositions comprising...
|
|
WO/2024/073013A1 |
The present disclosure is directed to topical compositions and methods for the treatment and/or amelioration of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation, including Dupuytren's disease, Dupu...
|
|
WO/2024/073721A1 |
Methods and postbiotic compositions which reduce fecal enzyme activity, as well as absorbent articles which comprise the postbiotic compositions are disclosed. The postbiotic compositions and absorbent articles of the present disclosure ...
|
|
WO/2024/069507A1 |
This invention relates to novel processes for synthesizing N-(3-(6-Amino-5-(2-(N- methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphe
nyl)-4-cyclopropyl-2-fluorobenzamide and to intermediates which are used in such processes.
|
|
WO/2024/071439A1 |
The present invention provides a novel compound that has an STAT6 inhibitory effect and is efficacious in treating inflammatory diseases and allergic diseases such as atopic dermatitis. A compound represented by general formula (I) and h...
|
|
WO/2024/072995A1 |
Provided herein is a composition for regenerating and rejuvenating a mammalian tissue in vivo. In some embodiments, the composition may comprise L-methionine, threonine, glycine, putrescine, cysteine and S-adenosylmethionine (SAM) in amo...
|
|
WO/2024/072793A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/067330A1 |
Provided is use of a pentacyclic triterpenoid compound in preparing a medicament for preventing and/or treating sarcoidosis. The pentacyclic triterpenoid compound has the advantages of causing small liver and kidney damage, being safe to...
|
|
WO/2024/067560A1 |
Disclosed in the present invention are a sulfonamide compound and the medical use thereof as a STING inhibitor, specifically, a compound as represented by formula (I) or a pharmaceutically acceptable salt or ester or solvate thereof, whi...
|
|
WO/2024/069634A1 |
The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of cancer in a subject in need thereof are also provided.
|
|
WO/2024/072794A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/065050A1 |
A method of preparing hair follicle-derived conditioned medium which comprises one or more bioactive factors, wherein the hair follicle is retrieved from a subject non-invasively, cultured in a culture medium for a duration sufficient fo...
|
|
WO/2024/069576A1 |
Novel crystalline forms of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N
- methylazetidin-3-amine 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N
- methylazetidin-3-amine mono succinate is provided along with ...
|
|
WO/2024/071959A1 |
The present invention relates to a method for synthesizing a derivative obtained by esterifying choline alfoscerate. The present invention also relates to a preparation comprising a choline alposcerate ester (TGPC) derivative and a use t...
|
|
WO/2024/067783A1 |
Provided are a compound represented by formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and use of the compound as an androgen receptor (AR) inhibitor.
|
|
WO/2024/067327A1 |
The present invention relates to use of a triterpenoid saponin compound with a general formula structure represented by formula A in the preparation of a medicament for preventing and/or treating nodule, fibrosis, or granuloma diseases, ...
|
|
WO/2024/073072A1 |
The invention is directed to topical formulations of a compound represented by the following structural formula: (I). Included are an ointment formulation of the compound, an anhydrous gel formulation of the compound, an aqueous gel form...
|
|
WO/2023/219376A9 |
The present invention relates to: a natural composition for inhibiting the production of carcinogenic N-nitrosamine in the stomach and intestines and promoting the production of nitric oxide in the intestines; and a use thereof. The natu...
|
|
WO/2024/069577A1 |
Novel crystalline forms of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N
- methylazetidin-3-amine is provided along with pharmaceutical compositions comprising the same. Also disclosed is the use of the novel polymorph for...
|
|
WO/2024/073011A1 |
The present disclosure is directed to topical compositions and methods for the treatment and/or amelioration of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation, including Dupuytren's disease, Dupu...
|
|
WO/2024/061476A1 |
Suggested is a non-therapeutic method for preventing, mitigating or treating PTGS2-induced disorders of human skin and related dysfunctions, comprising or consisting of the following step: - applying a working amount of a carnosine compo...
|
|
WO/2024/062127A1 |
Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispe...
|
|
WO/2024/063715A1 |
Effervescent Tablet Comprising L-Arginine Used for Healing Wounds The invention relates to a composition comprising L-arginine and a production method of said composition for use as a food supplement in order to heal wounds.
|
|
WO/2024/063480A1 |
The present invention relates to a pharmaceutical composition for moisturizing the skin or treating diseases in which skin barrier are weakened, comprising an RhoA-activating factor as an active ingredient. The present invention relates ...
|
|
WO/2024/063661A1 |
The subject matter of the invention is a pharmaceutical composition for topical application containing a beta- adrenergic receptor antagonist and a corticosteroid and use thereof in the treatment of hemangiomas in children.
|
|
WO/2024/062238A1 |
The present invention relates to a composition comprising a heterotrophic skin bacterium and/or heterotrophic skin bacterial extract for use in the modulation of cytokine expression in a skin cell. The composition is particularly suited ...
|
|
WO/2024/063424A1 |
The present invention relates to microspheres comprising baricitinib, a method for producing same, and a pharmaceutical composition comprising same. The microspheres comprising baricitinib, according to the present invention, exhibit sta...
|
|
WO/2024/061894A1 |
The present disclosure relates to the use of compounds such as compounds of Formula (I) or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, for example, in pharmaceutical compositions and in the treatment of diseases, ...
|
|
WO/2024/064898A2 |
Compositions and methods for treating cutaneous radiation injury (CRI), including radiation dermatitis, radiation proctopathy, or oral mucositis, employing one or more functional inhibitor of acid sphingomyelinase (FIASMA).
|
|
WO/2024/061187A1 |
Provided in the present disclosure are stilbene derivatives, a preparation method therefor and the use thereof. Specifically, provided in the present disclosure is the use of compounds represented by formula (I-1), and stereoisomers, pha...
|
|
WO/2024/063147A1 |
The present invention provides a compound represented by formula (I) and useful as a pharmaceutical product, or a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition for the treat...
|
|
WO/2024/064947A1 |
Disclosed herein are compositions and methods for inhibiting pigmentation of hair or skin. The compositions of the disclosure comprise an effective amount of a compound used for inhibition of pigmentation.
|
|
WO/2024/062023A1 |
A Neem tree leaf extract of the present invention is enriched in Nimbolide and/or depleted in Azadirachtin content compared to the relative average proportional content of these components in Neem tree leaves. A method for producing such...
|
